Olema Oncology (also known as Olema Pharmaceuticals) is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers. Its lead program, OP-1250, a potential complete estrogen receptor antagonist (CERAN), is in development to treat estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.